<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812916</url>
  </required_header>
  <id_info>
    <org_study_id>EXPRESSO</org_study_id>
    <nct_id>NCT00812916</nct_id>
  </id_info>
  <brief_title>European Carto® XP REgistry for Validating Specialized CFAE SOftware</brief_title>
  <acronym>EXPRESSO</acronym>
  <official_title>EXPRESSO - European Carto® XP REgistry for Validating Specialized CFAE SOftware</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster EMEA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective observational study (registry) is to determine the acute
      success rate of a complex fractionated atrial electrogram (CFAE) guided ablation procedure
      using a dedicated software and to determine the functionality and performance of the CFAE
      software in patients with a type of persistent atrial fibrillation (AF) in routine clinical
      practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multi-center, observational registry study evaluating CARTO® XP CFAE
      Software (CFAE Software) in subjects with chronic AF requiring CFAE-guided RFCA. Use of the
      CARTO® 3 System (including CFAE Software) was also allowed. The primary efficacy endpoint was
      the acute success rate of CFAE-guided radiofrequency catheter ablation (RFCA) using the CFAE
      Software. Acute success is defined as the subject achieving sinus rhythm at the end of the
      procedure without electrical or pharmaceutical cardioversion. Secondary endpoints consisted
      of measures of efficacy (example, performance of the CFAE Software) and of safety (example,
      number of procedure-related adverse events).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Success</measure>
    <time_frame>End of procedure</time_frame>
    <description>Sinus rhythm achieved at end of ablation procedure without electrical or pharmaceutical cardioversion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Ablation Time</measure>
    <time_frame>Procedural</time_frame>
    <description>Total time of ablation with exception of 10 outliers with &gt;180 minutes of total ablation time reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Complex Fractionated Atrial Electrogram (CFAE) Mapping Time</measure>
    <time_frame>Procedural</time_frame>
    <description>Total of left and right atrium CFAE mapping times with exception of 9 outliers reporting total CFAE mapping time of &gt;120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Radiofrequency (RF) Duration</measure>
    <time_frame>Procedural</time_frame>
    <description>Total duration of all radiofrequency applications with exception of 12 outliers recording &gt;150 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fluoroscopy Time</measure>
    <time_frame>Procedural</time_frame>
    <description>Mean total fluoroscopy time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Ablated Complex Fractionated Atrial Electrogram (CFAE) Discrete Points</measure>
    <time_frame>Procedural</time_frame>
    <description>Does not include 2 outliers with &gt;300 CFAE discrete points. Based on the user-defined definition of a CFAE complex, the system identifies the number of intervals between adjacent CFAE complexes and the cycle length of these intervals. This makes it possible to estimate the number of CFAE complexes within certain amplitude and duration values. A CFAE complex is defined by the system based on the intervals between the peaks. Therefore, clinically, the CFAE software includes an algorithm that enables detection of CFAE complexes. The automatic detection and distribution of CFAE signals is taking place during a 2.5 second intra-cardiac ECG recording. When the CFAE areas are completely eliminated, but the arrhythmia continues as organized atrial flutter or atrial tachycardia, the atrial tachy-arrhythmias may be mapped and ablated upon discretion of the investigator. Analyses occur post-procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">206</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>RF ablation</arm_group_label>
    <description>RF Ablation using specialized CFAE software</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RF ablation, using specialized CFAE software</intervention_name>
    <description>RF ablation</description>
    <arm_group_label>RF ablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent or longstanding persistent atrial fibrillation (AF), needing
        radiofrequency (RF) ablation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent or longstanding persistent AF

        Exclusion Criteria:

          -  Previously underwent RF ablation for AF and patients with paroxysmal AF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Albenque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur - Unité de Cardiologie interventionnelle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustin Bortone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Les Franciscaines Service Rhythmologie,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Pisapia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Joseph</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck Raczka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Arnaud de Villeneuve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Csaba Földesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gottsegen György Országos Kardiológiai Intézet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armin Luik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtisches Klinikum Karlsruhe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Abdelaal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles-Sélim Lande-Abbey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Laënnec - CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Cauchemez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ambroise Paré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Lellouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Henri Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Extramiana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière Service de Rhytmologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Seitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Jacques Cartier Service de Rhytmologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil CEDEX</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier Service de Rhytmologie</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise Paré</name>
      <address>
        <city>Neuilly sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Les Franciscaines Service Rhythmologie</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière Service de Rhytmologie</name>
      <address>
        <city>Paris CEDEX 10</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Laënnec - CHU de Nantes</name>
      <address>
        <city>St Herblain</city>
        <zip>44814</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - Unité de Cardiologie interventionnelle</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>November 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2015</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent or longstanding persistent atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Number of Patients</title>
          <description>Radiofrequency (RF) Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206">206 enrolled (consented)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Data Available</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CFAE - Guided Ablation</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled patients</population>
      <group_list>
        <group group_id="B1">
          <title>Radiofrequency (RF) Ablation</title>
          <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age and gender were not collected for this trial.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Age and gender were not collected for this trial.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Success</title>
        <description>Sinus rhythm achieved at end of ablation procedure without electrical or pharmaceutical cardioversion</description>
        <time_frame>End of procedure</time_frame>
        <population>Patients with CFAE-guided RF catheter ablation</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success</title>
          <description>Sinus rhythm achieved at end of ablation procedure without electrical or pharmaceutical cardioversion</description>
          <population>Patients with CFAE-guided RF catheter ablation</population>
          <units>percentage achieving success</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="41.7" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Ablation Time</title>
        <description>Total time of ablation with exception of 10 outliers with &gt;180 minutes of total ablation time reported</description>
        <time_frame>Procedural</time_frame>
        <population>Safety population with ablation time reported</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ablation Time</title>
          <description>Total time of ablation with exception of 10 outliers with &gt;180 minutes of total ablation time reported</description>
          <population>Safety population with ablation time reported</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Complex Fractionated Atrial Electrogram (CFAE) Mapping Time</title>
        <description>Total of left and right atrium CFAE mapping times with exception of 9 outliers reporting total CFAE mapping time of &gt;120 minutes</description>
        <time_frame>Procedural</time_frame>
        <population>Safety population with mapping time reported</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF Ablation using specialized CFAE software</description>
          </group>
        </group_list>
        <measure>
          <title>Total Complex Fractionated Atrial Electrogram (CFAE) Mapping Time</title>
          <description>Total of left and right atrium CFAE mapping times with exception of 9 outliers reporting total CFAE mapping time of &gt;120 minutes</description>
          <population>Safety population with mapping time reported</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Radiofrequency (RF) Duration</title>
        <description>Total duration of all radiofrequency applications with exception of 12 outliers recording &gt;150 minutes.</description>
        <time_frame>Procedural</time_frame>
        <population>Safety population with RF data reported</population>
        <group_list>
          <group group_id="O1">
            <title>RF Ablation</title>
            <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
          </group>
        </group_list>
        <measure>
          <title>Total Radiofrequency (RF) Duration</title>
          <description>Total duration of all radiofrequency applications with exception of 12 outliers recording &gt;150 minutes.</description>
          <population>Safety population with RF data reported</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fluoroscopy Time</title>
        <description>Mean total fluoroscopy time</description>
        <time_frame>Procedural</time_frame>
        <population>Safety population with fluoroscopy time reported</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluoroscopy Time</title>
          <description>Mean total fluoroscopy time</description>
          <population>Safety population with fluoroscopy time reported</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Ablated Complex Fractionated Atrial Electrogram (CFAE) Discrete Points</title>
        <description>Does not include 2 outliers with &gt;300 CFAE discrete points. Based on the user-defined definition of a CFAE complex, the system identifies the number of intervals between adjacent CFAE complexes and the cycle length of these intervals. This makes it possible to estimate the number of CFAE complexes within certain amplitude and duration values. A CFAE complex is defined by the system based on the intervals between the peaks. Therefore, clinically, the CFAE software includes an algorithm that enables detection of CFAE complexes. The automatic detection and distribution of CFAE signals is taking place during a 2.5 second intra-cardiac ECG recording. When the CFAE areas are completely eliminated, but the arrhythmia continues as organized atrial flutter or atrial tachycardia, the atrial tachy-arrhythmias may be mapped and ablated upon discretion of the investigator. Analyses occur post-procedure.</description>
        <time_frame>Procedural</time_frame>
        <population>Safety population with non-outlier endpoint reported</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>RF Ablation using specialized CFAE software</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Ablated Complex Fractionated Atrial Electrogram (CFAE) Discrete Points</title>
          <description>Does not include 2 outliers with &gt;300 CFAE discrete points. Based on the user-defined definition of a CFAE complex, the system identifies the number of intervals between adjacent CFAE complexes and the cycle length of these intervals. This makes it possible to estimate the number of CFAE complexes within certain amplitude and duration values. A CFAE complex is defined by the system based on the intervals between the peaks. Therefore, clinically, the CFAE software includes an algorithm that enables detection of CFAE complexes. The automatic detection and distribution of CFAE signals is taking place during a 2.5 second intra-cardiac ECG recording. When the CFAE areas are completely eliminated, but the arrhythmia continues as organized atrial flutter or atrial tachycardia, the atrial tachy-arrhythmias may be mapped and ablated upon discretion of the investigator. Analyses occur post-procedure.</description>
          <population>Safety population with non-outlier endpoint reported</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Peri-procedural, up to duration of study</time_frame>
      <desc>Procedure and/or device related</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiofrequency (RF) Ablation</title>
          <description>RF Ablation using specialized complex fractionated atrial electrogram (CFAE) software</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Epicardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sheath retained in femoral vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Phrenic nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nathalie Macours</name_or_title>
      <organization>Biosense Webster, EMEA</organization>
      <phone>+32 2 7463076</phone>
      <email>MNathalie@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

